Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.47

+0.3%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (3087)	3/14/2001 9:25:48 PM
From: Biomaven	Read Replies (1) of 52153

Ian, I'm not an accountant. I could be wrong. Well I'm not an accountant either, but I did design a program currently used to calculate diluted shares for over 400 public companies, so I as sure as hell better be right on this. <g> The standard here is set by FAS 128. If a company is not profitable on an operating basis, they report only basic shares outstanding. The reason for this is that if a company is making a loss, having more shares outstanding reduces the loss per share, and so only the more "conservative" basic shares number is reported. It's one of the traps for the unwary in valuing money-losing biotechs. <g> Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next